Stem Cell Transplant for Bone Marrow Failure Syndromes

Status Completed

Clinical Trial Summary

The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.

Clinical Trial Description

Prior to transplantation, subjects will receive the drugs busulfan (orally or through the catheter), as well as fludarabine and anti-thymocyte globulin (ATG) via the catheter. Busulfan, fludarabine and ATG will be given with Total Lymphoid Irradiation (TLI) to help the new donor bone marrow take and grow after transplantation.

Those patients receiving donor marrow will have the T cells (a type of white blood cell in the donor marrow) removed to lower the risk that the new marrow will react to their body, a condition called Graft-Versus-Host-Disease (GVHD). After bone marrow transplantation, subjects will receive drugs to help prevent GVHD, including cyclosporin and mycophenolate mofetil (MMF).

Blood samples are taken at day 28, day 60, day 100, 1 year and as required by medical status yearly for five years after transplant to evaluate how well the new marrow is growing. A bone marrow biopsy is required at day 21, at day 100 and 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00176878
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	June 2000
Completion date	March 2009

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00244010` - Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias	N/A
Terminated	`NCT00290628` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A
Completed	`NCT00673608` - Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload	Phase 4
Completed	`NCT01114776` - Multi-Center Study of Iron Overload: Pilot Study
Withdrawn	`NCT01419704` - Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies	Phase 1/Phase 2
Completed	`NCT01913548` - Multi-Center Study of Iron Overload: Survey Study (MCSIO)
Active, not recruiting	`NCT01966367` - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Completed	`NCT00957931` - Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs	Phase 2
Completed	`NCT00176852` - Stem Cell Transplant for Hemoglobinopathy	Phase 2/Phase 3
Recruiting	`NCT02720679` - Investigation of the Genetics of Hematologic Diseases
Completed	`NCT01917708` - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases	Phase 1
Completed	`NCT00301834` - Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders	Phase 2
Completed	`NCT01529827` - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Completed	`NCT02512679` - Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells	Phase 2
Completed	`NCT00305708` - Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission	Phase 1/Phase 2
Recruiting	`NCT03653338` - T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias	Phase 1/Phase 2
Recruiting	`NCT03050268` - Familial Investigations of Childhood Cancer Predisposition
Completed	`NCT01586455` - Human Placental-Derived Stem Cell Transplantation	Phase 1
Recruiting	`NCT04965597` - Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)	Phase 2